Oppenheimer Reiterates Perform Rating on Aastrom Biosciences on Discontinuation of Phase III REVIVE CLI

Loading...
Loading...
In a report published Wednesday, Oppenheimer analyst Boris Peaker reiterated a Perform rating on Aastrom Biosciences
ASTM
. In the report, Peaker noted, “Earlier today, Aastrom announced that it will discontinue the Phase III REVIVE CLI study, the company's most advanced program, and shift its focus toward the development of ixmyelocel-T for dilated cardiomyopathy (DCM). The company now expects to commence its Phase IIb ixCELL-DCM study of ixmyelocel-T for DCM in the coming weeks. Aastrom also announced that it will undertake corporate restructuring aimed at reducing staff and operating expenses by ~50%. Enrollment in the REVIVE-CLI study has been very slow with just 40 patients at the last update (3/19/2013). Aastrom has few near-term milestones and despite restructuring, it will need additional financing. We maintain our Perform rating.” Aastrom Biosciences closed on Tuesday at $0.73.
Posted In: Analyst ColorReiterationAnalyst RatingsOppenheimer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...